InspirationGP/iStock via Getty Images
The world’s largest meeting of cancer research is scheduled to begin this week. The annual meeting of the American Association for Cancer Research (AACR) is a sought-after event on the healthcare calendar, with many pharmaceutical companies scheduled to highlight their the latest oncology research at the multi-day conference.
The 2023 edition of the meeting, which will take place from April 14 to 19 in Orlando, Florida, is no exception, with leading biotechnologies such as Moderna (NASDAQ:MRNA) to the limit of SMID SpringWorks Therapeutics (NASDAQ: SWTX) scheduled to present some of the most anticipated readings.
The usual abstracts from the event were published in mid-March, along with clinical trial titles and breaking abstracts. However, full clinical trial results and breaking summaries will only be publicly available on April 14, when the meeting begins.
According to industry publication BiopharmIQ, more than 20 SMID capped biopharmaceuticals are on track to be introduced at AACR 2023, potentially leading to multiple stock movement events. The mere announcement of their upcoming presentations at the event sent shares of Sensei Biotherapeutics (SNSE) and Corbus Pharmaceuticals (CRBP) soaring last month.
Among large-cap biotechs, Moderna (MRNA) is set to follow up on its mid-stage trial for Merck-(New York Stock Exchange:MRK) was partnered with the personalized cancer vaccine mRNA-4157/V940 in a presentation and poster session scheduled for April 16 and 18, respectively.
In December, the duo raised hopes for a mRNA-based cancer vaccine after announcing their Phase 2b study trial for mRNA-4157/V940 and Merck’s (MRK) anti-PD-1 therapy Keytruda met the target. main in certain patients with skin problems. melanoma cancer
At the event, Eli Lilly (New York Stock Exchange: LLY) will mark its presence in the KRAS G12C space, where Amgen (AMGN) and Mirati Therapeutics (MRTX) dominate. On April 17, the Indianapolis, Indiana-based drugmaker is on track to detail the first clinical data from a Phase 1 trial of its KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors.
A day earlier, the company will present first human data on its IDH inhibitor LY3410738 from a Phase 1 trial for advanced myeloid malignancies and will then follow up with more early-stage data for the IDH-mutant advanced cholangiocarcinoma candidate. and other solid tumors. tumors
Relay Therapeutics (RLAY) and Kinnate Biopharma (KNTE) are also among the notable presenters at this year’s event after AACR selected the biotechs to present their first human data for the PI3Kα kinase inhibitor RLY-2608 and the pan-RAF inhibitor exarafenib in the event, respectively.
However, Bank of America is looking forward to the first clinical data that SpringWorks Therapeutics (SWTX) will present for its cancer candidate BGB-3245, qualifying the Phase 1 readout as a very important event at the conference.
The BeiGene-associated RAF inhibitor (BGNE) “could represent a billion-dollar therapy, although we note they are a long way off the market (we project 2027 launches),” analyst Alec Stranahan argued in a March note.
BofA also highlighted SWTX’s presentation on Phase 1 results for the combination of mirdametinib + lifirafenib in patients with advanced or refractory solid tumors, highlighting the read as another very important BCAA event.
Meanwhile, Erasca (ERAS) is set to publish Phase 1 data for its oral SHP2 inhibitor ERAS-601 at a poster session on April 18, marking another major clinical event in BofA coverage. The poster presentation will include the results of the initial dose escalation for ERAS-601 in combination with cetuximab, an FDA-approved cancer therapy, in patients with previously treated advanced or metastatic solid tumors.
Seeking Alpha analyst William Meyers sees BCAA 2023 as a potential catalyst for MiNK Therapeutics (INKT), which is set to update clinical data for its agenT-797 natural killer T cell therapy, as a combination therapy in advanced solid tumors.